Chemotherapy-Induced Nausea and Vomiting in Asian Women With Breast Cancer Receiving Anthracycline-Based Adjuvant Chemotherapy

Journal of Supportive Oncology

Volumn 10, Issue 4, 2012, Pages 149-154

  Bourdeanu, Laura ^a   Frankel, Paul ^b   Yu, Wai ^b   Hendrix, Gregory ^b   Pal, Sumanta ^b   Badr, Lina ^c   Somlo, George ^b   Luu, Thehang ^b,d  

^a Russell Sage College   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c AZUSA PACIFIC UNIVERSITY   (United States)

^d Department of Medical Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CAUCASIAN; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DISEASE SEVERITY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; RETROSPECTIVE STUDIES; VOMITING;

EID: 84862753588     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.10.007     Document Type: Article

References (24)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Hudis C.A., Schmitz N. Dose-dense chemotherapy in breast cancer and lymphoma. Semin Oncol 2004, 31(3)(suppl 8):19-26.
3. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10(suppl 3):20-29.
4. Roila F., Hesketh P.J., Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006, 17(1):20-28.
5. Jordan K., Kasper C., Schmoll H.J. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005, 41(2):199-205.
6. Andrykowski M.A., Gregg M.E. The role of psychological variables in post-chemotherapy nausea: anxiety and expectation. Psychosom Med 1992, 54(1):48-58.
7. Kaiser R., Sezer O., Papies A., et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002, 20(12):2805-2811.
8. Kim Y., Morrow G.R. Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 2003, 11(3):171-177.
9. Klosterhalfen S., Kellermann S., Pan F., Stockhorst U., Hall G., Enck P. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med 2005, 76(11):1051-1057.
10. Klosterhalfen S., Pan F., Kellerman S., Enck P. Gender and race as determinants of nausea induced by circular vection. Gend Med 2006, 3:236-242.
11. Martin C.G., Rubenstein E.B., Elting L.S., Kim Y.J., Osoba D. Measuring chemotherapy-induced nausea and emesis. Cancer 2003, 98(3):645-655.
12. McLauchlan R., Waterman H., Waterman C., Hillier V., Dodd C. Ethnic variation in fluorescein angiography induced nausea and vomiting. Eye (Lond) 2001, 15(pt 2):159-162.
13. Morrow G.R., Roscoe J.A., Hickok J.T., Andrews P.R., Matteson S. Nausea and emesis: evidence for a biobehavioral perspective. Support Care Cancer 2002, 10(2):96-105.
14. Morrow G.R., Roscoe J.A., Kirshner J.J., Hynes H.E., Rosenbluth R.J. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998, 6(3):244-247.
15. Osoba D., Zee B., Warr D., Latrelle J., Kaizer L., Pater J. Effect of post chemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 1997, 5:307-313.
16. Sullivan J.R., Leyden M.J., Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 1983, 309(13):796.
17. Hulley B., Cummings S.R., Browner W.S., Grady D., Hearst N., Newman T.B. Designing Clinical Research 2001, Lippincott Williams & Wilkins, Philadelphia, PA.
18. Munro B.H. Statistical Research for Health Care Research 2005, Lippincott Williams & Wilkins, Philadelphia, PA. 5th ed.
19. National Comprehensive Network. NCCN Guidelines for Supportive Care, 2010 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
20. Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 2010, National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
21. Stern R.M., Hu S., LeBlanc R., Koch K.L. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat Space Environ Med 1993, 64(9, pt 1):827-830.
22. Stern R.M., Hu S., Uijtdehaage S.H., Muth E.R., Xu L.H., Koch K.L. Asian hypersusceptibility to motion sickness. Hum Hered 1996, 46(1):7-14.
23. Bernard S., Neville K.A., Nguyen A.T., Flockhart D.A. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006, 11:126-135.
24. Hassan B.A., Yusoff Z.B. Genetic polymorphisms in the three Malaysian races affect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 2011, 12(1):185-191.